TSE:4502Pharmaceuticals
What Takeda Pharmaceutical (TSE:4502)'s Pediatric ENTYVIO Phase 3 Success Means For Shareholders
In February 2026, Takeda announced positive Phase 3 KEPLER trial results showing ENTYVIO (vedolizumab) induced clinical remission in children aged 2–17 with moderately to severely active ulcerative colitis, and said it plans regulatory submissions in the US, EU and other markets.
The data highlight ENTYVIO’s potential to extend a key gastroenterology therapy into a pediatric population where treatment options are limited, reinforcing Takeda’s focus on high-need specialty indications.
We’ll...